Published in Lancet on July 23, 2015
Metastatic colonization by circulating tumour cells. Nature (2016) 1.31
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis (2015) 0.94
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press) (2016) 0.87
Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86
Adjuvant systemic therapy in older women with breast cancer. Breast Cancer (Dove Med Press) (2016) 0.85
Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol (2016) 0.83
Analysis of Immune Cells from Human Mammary Ductal Epithelial Organoids Reveals Vδ2+ T Cells That Efficiently Target Breast Carcinoma Cells in the Presence of Bisphosphonate. Cancer Prev Res (Phila) (2016) 0.81
Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis. Endocrinol Metab (Seoul) (2016) 0.80
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials. Eur J Cancer (2015) 0.80
The bone microenvironment - Multiple players involved in cancer progression. J Bone Oncol (2016) 0.79
Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. Bonekey Rep (2015) 0.79
SEOM Clinical Guideline for bone metastases from solid tumours (2016). Clin Transl Oncol (2016) 0.79
Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials (2015) 0.78
Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake? Sci Rep (2016) 0.78
In vivo models in breast cancer research: progress, challenges and future directions. Dis Model Mech (2017) 0.78
Omentum and bone marrow: how adipocyte-rich organs create tumour microenvironments conducive for metastatic progression. Obes Rev (2016) 0.77
Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. Br J Cancer (2016) 0.76
The role of lysyl oxidase, the extracellular matrix and the pre-metastatic niche in bone metastasis. J Bone Oncol (2016) 0.76
Bone metastasis risk factors in breast cancer. Ecancermedicalscience (2017) 0.75
[In Process Citation]. Perspect Infirm (2016) 0.75
Management of Potential Long-Term Toxicities in Breast Cancer Patients. Curr Breast Cancer Rep (2016) 0.75
Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole. Onco Targets Ther (2016) 0.75
Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcif Tissue Int (2016) 0.75
Assessment of bone health in breast cancer patients starting adjuvant aromatase inhibitors: A quality improvement clinical audit. J Bone Oncol (2016) 0.75
Bisphosphonates, bone, and breast cancer recurrence. Lancet (2015) 0.75
Reimbursement for bone loss prevention is different between women with breast cancer and men with prostate cancer: time for a revision. Facts Views Vis Obgyn (2015) 0.75
Future directions for bone metastasis research - highlights from the 2015 bone and the Oncologist new updates conference (BONUS). J Bone Oncol (2016) 0.75
Strategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions. J Bone Oncol (2016) 0.75
Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. Sci Rep (2016) 0.75
Therapeutic interactions between mesenchymal stem cells for healing medication-related osteonecrosis of the jaw. Stem Cell Res Ther (2016) 0.75
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkers. Breast Cancer Res (2016) 0.75
Dosing of zoledronic acid with its anti-tumor effects in breast cancer. J Bone Oncol (2015) 0.75
Bone targeted treatments in cancer - The story so far. J Bone Oncol (2016) 0.75
Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo. Oncotarget (2016) 0.75
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol (2017) 0.75
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? Int J Mol Sci (2016) 0.75
Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells. Breast Cancer Res (2017) 0.75
Reproductive hormones in breast cancer bone metastasis: The role of inhibins. J Bone Oncol (2016) 0.75
Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. Menopause (2016) 0.75
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Geburtshilfe Frauenheilkd (2017) 0.75
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
Osteonecrosis of the jaw and survival of patients with cancer: a nationwide cohort study in Denmark. Cancer Med (2017) 0.75
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score. J Bone Oncol (2016) 0.75
The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate). J Bone Miner Res (2017) 0.75
Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. PLoS One (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Sequence and organization of the human mitochondrial genome. Nature (1981) 57.39
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer (1977) 53.23
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Mortality in relation to smoking: 20 years' observations on male British doctors. Br Med J (1976) 28.28
The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst (1981) 25.60
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet (1990) 25.12
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 24.57
Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ (1994) 23.80
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer (1976) 22.55
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics (1973) 18.14
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med (2013) 13.90
A long-term follow-up study of women using different methods of contraception--an interim report. J Biosoc Sci (1976) 13.09
The natural history of chronic airflow obstruction. Br Med J (1977) 13.04
Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet (2004) 12.59
Complete sequence of bovine mitochondrial DNA. Conserved features of the mammalian mitochondrial genome. J Mol Biol (1982) 11.71
Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ (1998) 10.71
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 10.62
Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials. Eur Heart J (1985) 9.28
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet (2004) 9.10
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Social class analysis--an embarrassment to epidemiology. Community Med (1984) 8.50
Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med (1997) 8.25
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (2011) 8.24
Shotgun DNA sequencing using cloned DNase I-generated fragments. Nucleic Acids Res (1981) 8.23
Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. J Epidemiol Community Health (1978) 7.80
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
Why do we need some large, simple randomized trials? Stat Med (1985) 7.67
Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet (2015) 7.29
UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet (2000) 7.19
Chronic infections and coronary heart disease: is there a link? Lancet (1997) 7.18
Disruption of two novel genes by a translocation co-segregating with schizophrenia. Hum Mol Genet (2000) 7.16
Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) (1988) 6.76
Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors. BMJ (1994) 6.74
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet (2008) 6.67
Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol (1999) 6.42
Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ (1998) 6.13
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 6.02
Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst (1999) 5.92
Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.86
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med (1988) 5.81
Determinants and consequences of smoke-free homes: findings from the International Tobacco Control (ITC) Four Country Survey. Tob Control (2006) 5.63
Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet (2005) 5.50
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ (1991) 5.45
Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med (1995) 5.45
Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med (1995) 5.27
Mortality in relation to smoking: 22 years' observations on female British doctors. Br Med J (1980) 5.21
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (2011) 5.08
A short primer for sequencing DNA cloned in the single-stranded phage vector M13mp2. Nucleic Acids Res (1980) 4.98
Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol (1996) 4.92
The relevance in adults of air-flow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis (1983) 4.90
Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst (2004) 4.83
Mortality among doctors in different occupations. Br Med J (1977) 4.60
Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. BMJ (1998) 4.51
Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol (1994) 4.50
Sudden fall in breast cancer death rates in England and Wales. Lancet (1995) 4.50
Can dietary beta-carotene materially reduce human cancer rates? Nature (1981) 4.43
The factor structure and factor stability of the hospital anxiety and depression scale in patients with cancer. Br J Psychiatry (1991) 4.43
Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet (2000) 4.39
A novel progressive spongiform encephalopathy in cattle. Vet Rec (1987) 4.39
Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet (2008) 4.35
Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 4.31
Tobacco--the growing epidemic. Nat Med (1999) 4.31
Distinctive sequence of human mitochondrial ribosomal RNA genes. Nature (1980) 4.30
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 4.24
Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. JAMA (1997) 4.09
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum (1990) 3.97
Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens (1988) 3.86
A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med (1989) 3.83
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (2005) 3.75
Different pattern of codon recognition by mammalian mitochondrial tRNAs. Proc Natl Acad Sci U S A (1980) 3.74
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol (2005) 3.62
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Fundamental carcinogenic processes and their implications for low dose risk assessment. Cancer Res (1976) 3.58
Swallowing function after stroke: prognosis and prognostic factors at 6 months. Stroke (1999) 3.57